Synthon announced today that it has successfully concluded its registration procedures for Levocetirizine. Regulatory clearance has been obtained for Synthon's product in fourteen European countries using decentralized procedures. Registration has been established for 5 mg filmcoated tablets. Synthon's product is a fully bioequivalent version of the oral anti-histamine drug Xyzal®. The product contains the active ingredient levocetirizine, which is the enantiopure form of cetirizine, the active ingredient in UCB’s product Zyrtec®.